Should the FDA support app-based contraception? Advocates, experts disagree

Earlier this month, the FDA approved a contraception app for smartphones that claims to help users prevent pregnancy by monitoring body temperature and menstrual cycles. But critics are questioning the FDA’s move, pointing out that dozens of users got pregnant while using the app.

The Natural Cycles app uses the “fertility awareness” approach to preventing pregnancy. With the FDA’s approval, some wonder if users will (incorrectly) assume such methods are equally successful as oral medications or intrauterine devices.

"People will interpret this to mean that the FDA approves this and thinks it's a good method," said Christopher Zahn, MD, vice president of practice activities for the American College of Obstetricians and Gynecologists, in an interview with Kaiser Health News. "That's why counseling is so important," he says, noting that doctors should discuss all forms of birth control with women, and the conversation should include the efficacy of different methods.”

But some welcome the FDA’s willingness to accept non-traditional methods of contraception.

"More options are always better," said Gillian Dean, MD, senior director of medical services at Planned Parenthood Federation of America. "It isn't one size fits all, and more options increases the likelihood that women will find a method that works for their needs."

For more about the debate, visit the NPR/Kaiser Health News link below:

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”